Immunotherapy for squamous cell carcinoma with oncolytic virus

2015 Fiscal Year Final Research Report

• Project/Area Number: 24390453
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Osaka University
• Principal Investigator: YURA YOSHIAKI 大阪大学, 歯学研究科(研究院), 教授 (00136277)
• Co-Investigator(Renkei-kenkyūsha): IWAI SOICHI 大阪大学, 歯学部附属病院, 講師 (10362675) ; HAMADA MASAKAZU 大阪大学, 大学院歯学研究科, 助教 (80506361)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: 腫瘍融解性ウイルス療法 / 単純ヘルペスウイルス1型 / 扁平上皮癌 / 腫瘍免疫 / オートファジー / 免疫細胞 / プロテオーム解析

Outline of Final Research Achievements

Oncolytic virotherapy is based on the ability of virus to destroy tumor cells. We investigated whether the oncolytic herpes simplex virus type 1 (HSV-1) RH2 exerted an enhancing effect on tumor immunity for squamous cell carcinoma. In a bilateral tumor model with synergistic mice, tumors in one side were injected with RH2 and other side tumors left untreated. The growth of tumors of RH2-treated animals was reduced in both sides than that in untreated mice, indicating the enhancement of tumor immunity by RH2. In RH2-infected SCC cells, damage-associated molecular patterns (DAMPs) were produced. Proteome analysis revealed the presence of DAPMs in the supernatants of RH2-infected cells. These results indicate that RH2 stimulates tumor immunity through the function to produce immunogenic proteins including DAMPs.

Free Research Field

口腔外科学